Envoy Medical Inc. (NASDAQ: COCH), a leader in hearing health technology, has announced its financial results for the second quarter ending June 30, 2025. The company reported a $10,000 increase in net revenues for this period compared to the same quarter in 2024. General and administrative expenses rose by $0.5 million, primarily due to a $0.3 million severance accrual. Research and development expenses decreased by $0.1 million, totaling $2.485 million, as the company transitioned from the development phase to clinical trials. The company is experiencing strong momentum in the pivotal clinical trial of its fully implanted Acclaim® cochlear implant, with successful activation of all 10 study participants' implants. Envoy Medical remains optimistic about its strategic investments, especially given potential changes in reimbursement policies that could enhance the market position of the FDA-approved Esteem® fully implanted active middle ear implant. As of the end of the quarter, Envoy Medical's cash reserves stood at approximately $5.3 million.